Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Regulatory News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive iPSC data presented at conference

8 Dec 2022 07:06

RNS Number : 9871I
ReNeuron Group plc
08 December 2022


ReNeuron Group plc

("ReNeuron" or the "Company")


Positive induced pluripotent stem cell data presented at industry conference


ReNeuron presents new data highlighting the advantages of its novel type of iPSCs including data

from the Company's collaboration with University College London


ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosomes technologies, announces that one of its lead scientists, Dr Steve Pells, yesterday presented new data on the advantages of its induced pluripotent stem cells (iPSCs) including data from the Company's collaboration with University College London (UCL), at a major industry conference on iPSC-Derived Cell Therapies.


Key highlights from the presentation entitled Conditionally Immortalised iPSCs: A New Approach to Off-the-Shelf Allogeneic iPSC-Derived Cell Therapies included:


· Data was presented on the benefits of ReNeuron's novel type of iPSCs, known as Conditionally Immortalised Induced Pluripotent Stem Cells (CI-iPSCs)

· CI-iPSCs can differentiate into any cell type found in the human body, however unlike classical iPSCs, the addition of the conditional immortalisation technology gives greater control of the growth and survival of the subsequent differentiated cells, making them easier to grow in large quantities, purify and bank

· Data was presented highlighting how the use of CI-iPSCs lead to the manufacture of stable Schwann cells for the treatment of peripheral nerve damage repair

· This feature of CI-iPSCs also provides the ideal pluripotent stem cell line for the development of "off the shelf" stem cell-based therapies with work ongoing at UCL


The presentation will be available shortly on the Company's website: https://www.reneuron.com/investors/presentations/


Dr Randolph Corteling, Chief Scientific Officer, commented: "The data presented yesterday really highlights the potential for the use of ReNeuron's proprietary conditionally immortalised iPSCs in the treatment of peripheral nerve damage repair and the development of "off the shelf" stem cell-based therapies. Additionally, our CI-iPSCs are a key enabling technology for the expansion of the Company's CustomExTM exosome platform that allows growth beyond ReNeuron's current seven distinct exosome producing stem cell lines, therefore offering further ability to customise the exosome cell type for partners' needs and the payload / target cell of their choice."


CustomExTM is a register trademark of ReNeuron Limited








Catherine Isted, Chief Executive Officer

Via Walbrook PR

John Hawkins, Chief Financial Officer




Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

Alice Woodings / Paul McManus

+44 (0)7407 804 654 / +44 (0)7980 541 893



About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell derived Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.


ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.


The Company has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-licence both these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Date   Source Headline
26th Jun 20243:33 pmRNSChange of Registered Address
5th Jun 20243:36 pmRNSCreditor’s decision on Administrators' Proposals
17th May 202412:45 pmRNSPublication of Joint Administrators' Proposals
8th May 20247:00 amRNSUpdate on Administration Process
17th Apr 202411:30 amRNSDirectorate Change
20th Mar 20243:43 pmRNSAppointment of Administrators
20th Mar 202412:30 pmRNSIntention to Appoint Administrators
1st Mar 20247:00 amRNSBlock Listing Review & Total Voting Rights
5th Feb 20242:30 pmRNSCorporate update and suspension of trading on AIM
5th Feb 20242:30 pmRNSSuspension - ReNeuron Group plc
27th Nov 20238:53 amEQSEdison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™
8th Nov 20237:01 amRNSInterim Results for the six months ended 30 Sept
8th Nov 20237:00 amRNSReNeuron presents in vivo data at Cell 2023
4th Sep 20237:00 amRNSR&D Update
1st Sep 20237:00 amRNSBlock Listing Review & Total Voting Rights
29th Aug 20237:00 amRNSDirector declaration
22nd Aug 202310:34 amRNSResult of AGM
24th Jul 20235:20 pmRNSNotice of AGM
12th Jul 202311:57 amRNSShare Purchase by Chief Financial Officer
16th Jun 20235:12 pmRNSShare Purchase by Senior Independent NED
16th Jun 20232:26 pmRNSShare Purchase by Executive Chairman
16th Jun 20237:00 amRNSPosting of Annual Report & Accounts
5th Jun 20234:30 pmRNSHolding(s) in Company
25th May 20237:00 amRNSUnaudited Preliminary Results
18th May 20237:00 amRNSNotice of Results
17th May 20238:56 amRNSHolding(s) in Company
27th Apr 20238:18 amRNSHolding(s) in Company
6th Apr 20234:17 pmRNSShare Purchase by Senior Independent NED
3rd Apr 20237:00 amRNSNew Scientific Advisory Board
28th Mar 20232:23 pmRNSDirector/PDMR Shareholding
23rd Mar 20237:00 amRNSChange of adviser
13th Mar 20237:00 amRNSReNeuron to present at Advanced Therapies 2023
9th Mar 20234:03 pmRNSHolding(s) in Company
3rd Mar 20239:37 amRNSShare Purchase by Chief Financial Officer
1st Mar 20237:01 amRNSBlock listing application
1st Mar 20237:00 amRNSBlock Listing Review & Total Voting Rights
24th Feb 202311:20 amRNSDirector Share Purchases
15th Feb 20237:00 amRNSGrant of Options
30th Jan 20234:38 pmRNSDirector/PDMR Shareholding
27th Jan 202311:05 amRNSSecond Price Monitoring Extn
27th Jan 202311:00 amRNSPrice Monitoring Extension
24th Jan 202310:55 amRNSShare Purchase by Chief Financial Officer
23rd Jan 20233:04 pmRNSShare Purchase by Executive Chairman
19th Jan 20237:00 amRNSCompany restructuring update
3rd Jan 20237:02 amRNSTotal Voting Rights
3rd Jan 20237:00 amRNSDirectorate Change
12th Dec 20222:31 pmRNSHolding(s) in Company
8th Dec 20227:06 amRNSPositive iPSC data presented at conference
2nd Dec 20224:40 pmRNSSecond Price Monitoring Extn
2nd Dec 20224:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.